Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
The Source
TWSJ
Tech
It’s the Deadliest Room in the House—Especially for Seniors
TWSJ·21h ago·3 min read
Sports
Nighttime Drug Tests Have Become the Talk of the Tour de France
TWSJ·1h ago·3 min read
Business
Blackstone’s Profit Surges on AI Investments
TWSJ·1h ago·3 min read
Business
Harley-Davidson Raises Outlook on Strong North American Sales
TWSJ·58m ago·3 min read
Related
On this beat
Health
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
CNBC·1h ago·3 min read
Health
Ozempic face? Botox maker reports boost from ‘sagging face’ trend
CNBC·1h ago·3 min read
Health
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
TNYT·3h ago·3 min read
Health
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
TNYT·3h ago·3 min read